Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients

Table 2 Main characteristics of the approved direct acting antivirals that are currently used in interferon-free regimens for the treatment of chronic hepatitis C

Name	Category, antiviral activity	Doses	Adjustments
Simeprevir	Second-wave NS3/4A protease inhibitor, genotypes 1 and 4	150 mg daily, orally	No renal adjustment is needed
			Contraindicated in patients with Child-Pugh B/C
			Contraindicated cyclosporine co-administration
Sofosbuvir	NS5B RNA Polymerase nucleotide inhibitor, pangenotypic	400 mg daily, orally	Only in glomerular filtration rate > 30 mL/min
			No CNI adjustment is needed
Daclatasvir	NS5A inhibitor, genotypes 1, 3 and 4	60 mg daily, orally	No renal adjustment is needed
			No CNI adjustment is needed
Ledipasvir	NS5A inhibitor genotypes 1, 3 and 4	90 mg daily, orally (fixed dose with sofosbuvir)	No renal adjustment is needed1
			No CNI adjustment is needed
Dasabuvir	Non-NUC NS5B polymerase inhibitor genotype 1	250 mg every 12 h	No renal adjustment is needed
Paritaprevir/Ritonavir/Ombitasvir	Ritonavir boosted NS3/4A protease inhibitor/NS5A inhibitor, genotypes 1 and 4	75/50/12.5 mg x 2 once daily	No safety data in Child-Pugh B, contraindicated in Child-Pugh C
			Cyclosporine: 20% of pretreatment total daily dose; tacrolimus: 0.2 mg/72 h or 0.5 mg once weekly

¹Ledipasvir in combination with sofosbuvir should not be given in patients with glomerular filtration rate < 30 mL/min. CNI: Calcineurin inhibitor.